News

Home/ News & Events

ESID 1st PID Care in development School NEW Deadline -24th of May! Apply Now!

ESID 1st PID Care in development School is oriented to professionals in the need of expanding their knowledge on Primary Immunodeficiencies for their daily work, due to the absence of reference centers for PIDs in their surroundings.

Location: Hotel Academia, Zagreb, Croatia
Dates: September 15th-17th 2022

"Call for participation" IDDA2.1 score - an ESID registry prospective study

The IDDA score has already been available as optional module (tab) in the level 1 for your own use at the initial and follow up patient entries and is designed for all IEI with immune dysregulation. Now, I am inviting your active contribution to a prospective study until end of 2023 (prolongation possible), aiming to implement a powerful tool for assessment and monitoring of disease activity and phenotype patterns!

ESID COVID-19 Statement, March 2022

Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.

ESID Position Statement

ESID Position Statement

Joint statement of solidarity and support

ESID is profoundly concerned about the grave repercussions of the conflict in Ukraine on PID community, healthcare and patients. 

Together with IPOPI, INGID and J Project stakeholders, we have released a statement of solidarity and support to those impacted by the war in Ukraine.

Hyper IgM Grant opportunity

ESID is pleased to announce an excellent grant funding opportunity

Study on clinical course of IPEX patients infected with SARS-CoV-2

Call for international contributions relating to IPEX patients infected with SARS-CoV-2.

X-Linked Carrier Survey is now open

The Hyper IgM Foundation and the Wiskott-Aldrich Foundation’s first-ever international 

X-Linked Carrier Surveys are now available! We are excited to launch this survey project in collaboration with the Primary Immune Deficiency Treatment Consortium (PIDTC) and the Immune Deficiency Foundation (IDF).